Keywords: Canada, Pharma investment, Rx&D, KPMG, Underreporting

Innovative pharma investment in Canada has been underreported by 20% in the past, new study shows

Article | 21 June 2011

According to a new study by analysts at KPMG in conjunction with Canada’s pharmaceutical trade group Rx& ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in